CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) $ in Thousands	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2025	Jun. 30, 2024	Jun. 30, 2025	Jun. 30, 2024	Dec. 31, 2024
Income Statement [Abstract]
Net revenues	$ 158,805	$ 150,356	$ 313,799	$ 288,859	$ 605,220
Cost of revenues	41,472	34,654	79,993	68,343	137,181
Gross profit	117,333	115,702	233,806	220,516	468,039
Operating costs and expenses:
Research, development and clinical studies	55,833	54,955	109,610	106,553	209,645
Sales and marketing	57,066	56,616	112,858	111,822	239,063
General and administrative	43,955	37,711	88,724	77,241	189,827
Total operating costs and expenses	156,854	149,282	311,192	295,616	638,535
Operating income (loss)	(39,521)	(33,580)	(77,386)	(75,100)	(170,496)
Financial income (expenses), net	4,542	10,851	12,112	20,729	39,334
Income (loss) before income tax	(34,979)	(22,729)	(65,274)	(54,371)	(131,162)
Income tax	5,160	10,646	9,184	17,764	37,465
Net income (loss)	$ (40,139)	$ (33,375)	$ (74,458)	$ (72,135)	$ (168,627)
Basic net income (loss) per ordinary share (in usd per share)	$ (0.36)	$ (0.31)	$ (0.67)	$ (0.67)	$ (1.56)
Diluted net income (loss) per ordinary share (in usd per share)	$ (0.36)	$ (0.31)	$ (0.67)	$ (0.67)	$ (1.56)
Weighted average number of ordinary shares used in computing basic net income (loss) per share (in shares)	111,572,191	107,700,284	110,930,576	107,483,241	107,834,368
Weighted average number of ordinary shares used in computing diluted net income (loss) per share (in shares)	111,572,191	107,700,284	110,930,576	107,483,241	107,834,368